Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn’s disease: results from the EVOLVE studyGerassimos J. Mantzaris, Andrés Yarur, Song Wang et al.|European Journal of Gastroenterology & Hepatology|2023Cited by 9
DOP60 Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study dataGerassimos J. Mantzaris, Brian Bressler, Andrés Yarur et al.|Journal of Crohn s and Colitis|2021Cited by 7
Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn’s Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE StudyAndrés Yarur, Brian Bressler, Gerassimos J. Mantzaris et al.|Advances in Therapy|2024Cited by 5
Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn’s DiseaseAndrés Yarur, Gerassimos J. Mantzaris, Shashi Adsul et al.|Journal of Clinical Gastroenterology|2024Cited by 3